Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 6/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873834 | 0.91 | BACE1 (0.33) | GHSRBACE1KCNH2 | |
| SCHEMBL4877253 | 0.82 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL4876350 | 0.77 | ALDH1A1 (0.32) | KCNH2 | |
| SCHEMBL5231631 | 0.76 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4877772 | 0.74 | KDM4E (0.34) | KCNH2 | |
| SCHEMBL4874128 | 0.74 | SLC8A1 (0.33) | KCNH2 | |
| SCHEMBL4876725 | 0.74 | KMT2A (0.41) | — | |
| SCHEMBL2998895 | 0.74 | KMT2A (0.38) | BACE1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4875250 | 0.73 | KMT2A (0.41) | — | |
| SCHEMBL4868398 | 0.73 | HDAC1 (0.32) | BACE1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GHSR 4484/4885BACE1 4381/4885CHRNB2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.